68 Ga-FAPI-04 PET/CT and 18 F-FDG PET/CT in Metastatic Papillary Renal Cell Cancer.

Civan C., Isik E. G., Karadogan S., Sanli Y., Kuyumcu S.

Clinical nuclear medicine, vol.48, no.5, 2023 (SCI-Expanded, Scopus) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 48 Issue: 5
  • Publication Date: 2023
  • Doi Number: 10.1097/rlu.0000000000004587
  • Journal Name: Clinical nuclear medicine
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE
  • Keywords: 18F-FDG, 68Ga-FAPI, papillary renal cell carcinoma, PET/CT
  • Istanbul University Affiliated: Yes

Abstract

Papillary renal cell cancer is a rare malignancy with limited treatment options in the advanced stage of the disease. We present the case of a 62-year-old man with progressive left-sided papillary renal cell carcinoma who underwent 68Ga-FAPI (fibroblast activated protein inhibitor)-04 and 18F-FDG PET/CT imaging. 68Ga-FAPI-04 PET/CT demonstrated variable FAP expression in all metastatic lesions detected by 18F-FDG PET/CT, including multiple lymph nodes, bone, and thyroid. This case highlights that FAP-Targeted imaging can be a promising modality for diagnostic and theranostic use in papillary renal cell carcinoma.